Bafna Pharmaceuticals Limited (BAFNAPH.NS)
INR 78.05
(-4.33%)
INR 78.05
(-4.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 114.58 Million INR | -41.48% |
| 2022 | 189.88 Million INR | 42.5% |
| 2021 | 115.03 Million INR | 28.21% |
| 2020 | 106.23 Million INR | 636.45% |
| 2019 | 13.89 Million INR | 143.0% |
| 2018 | -126.9 Million INR | 60.09% |
| 2017 | -37.99 Million INR | -67.72% |
| 2016 | -50.94 Million INR | -677.16% |
| 2015 | 14.26 Million INR | 106.16% |
| 2014 | -128.68 Million INR | -156.71% |
| 2013 | 246.98 Million INR | 7.65% |
| 2012 | 245.16 Million INR | 12.34% |
| 2011 | 189.02 Million INR | 70.52% |
| 2010 | 120.88 Million INR | 38.2% |
| 2009 | 80.21 Million INR | 32.89% |
| 2008 | 59.08 Million INR | 188.69% |
| 2007 | 22.1 Million INR | 10.77% |
| 2006 | 19.93 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 8.66 Million INR | -59.7% |
| 2023 Q2 | 41.62 Million INR | -49.01% |
| 2023 Q4 | 28.87 Million INR | 363.47% |
| 2023 FY | - INR | -41.48% |
| 2023 Q3 | -10.95 Million INR | -126.33% |
| 2023 Q1 | 81.64 Million INR | 3.61% |
| 2022 FY | - INR | 42.5% |
| 2022 Q1 | 29.61 Million INR | 21.31% |
| 2022 Q2 | 31.83 Million INR | 7.52% |
| 2022 Q3 | 49.64 Million INR | 55.92% |
| 2022 Q4 | 78.79 Million INR | 58.73% |
| 2021 Q4 | 24.4 Million INR | -26.53% |
| 2021 Q1 | 36.54 Million INR | -5.26% |
| 2021 FY | - INR | 28.21% |
| 2021 Q2 | 58.73 Million INR | 60.74% |
| 2021 Q3 | 33.22 Million INR | -43.44% |
| 2020 Q1 | 27.75 Million INR | -20.85% |
| 2020 FY | - INR | 636.45% |
| 2020 Q4 | 38.56 Million INR | 71.58% |
| 2020 Q3 | 22.47 Million INR | 48.52% |
| 2020 Q2 | 15.13 Million INR | -45.47% |
| 2019 Q1 | -25.65 Million INR | -50.18% |
| 2019 FY | - INR | 143.0% |
| 2019 Q4 | 35.06 Million INR | -84.02% |
| 2019 Q3 | 219.38 Million INR | 10042.63% |
| 2019 Q2 | 2.16 Million INR | 108.43% |
| 2018 Q2 | 1.48 Million INR | 121.05% |
| 2018 FY | - INR | 60.09% |
| 2018 Q4 | -17.08 Million INR | -215.22% |
| 2018 Q3 | 14.82 Million INR | 898.92% |
| 2018 Q1 | -7.05 Million INR | 0.0% |
| 2017 FY | - INR | -67.72% |
| 2016 FY | - INR | -677.16% |
| 2015 FY | - INR | 106.16% |
| 2014 FY | - INR | -156.71% |
| 2013 FY | - INR | 7.65% |
| 2012 Q1 | 65.25 Million INR | 0.0% |
| 2012 Q2 | 82.42 Million INR | 26.31% |
| 2012 Q3 | 65.57 Million INR | -20.45% |
| 2012 Q4 | 29.74 Million INR | -54.64% |
| 2012 FY | - INR | 12.34% |
| 2011 FY | - INR | 70.52% |
| 2010 FY | - INR | 38.2% |
| 2009 FY | - INR | 32.89% |
| 2008 FY | - INR | 188.69% |
| 2007 FY | - INR | 10.77% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | 87.029% |
| Ind-Swift Limited | 1.06 Billion INR | 89.242% |
| Bajaj HealthCare Limited | 406.23 Million INR | 71.794% |
| Sakar Healthcare Limited | 393.26 Million INR | 70.864% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.815% |
| Innova Captab Limited | 1.66 Billion INR | 93.132% |
| Divi's Laboratories Limited | 25.43 Billion INR | 99.549% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 95.138% |
| Morepen Laboratories Limited | 1.72 Billion INR | 93.361% |
| Mankind Pharma Limited | 28.09 Billion INR | 99.592% |
| Sequent Scientific Limited | 549.8 Million INR | 79.159% |
| Wanbury Limited | 985.49 Million INR | 88.373% |
| Laurus Labs Limited | 8 Billion INR | 98.569% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 92.538% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 98.33% |
| Alembic Limited | 1.11 Billion INR | 89.736% |
| Hikal Limited | 2.69 Billion INR | 95.744% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 98.808% |
| Neuland Laboratories Limited | 4.74 Billion INR | 97.587% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 98.773% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 98.99% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 95.604% |
| Themis Medicare Limited | 562.6 Million INR | 79.634% |
| RPG Life Sciences Limited | 1.28 Billion INR | 91.059% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 99.796% |
| Lupin Limited | 36.96 Billion INR | 99.69% |
| Amrutanjan Health Care Limited | 681.59 Million INR | 83.189% |
| Wockhardt Limited | 1.08 Billion INR | 89.39% |
| Vaishali Pharma Limited | 31.71 Million INR | -261.335% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 97.069% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | 64.576% |
| Jubilant Pharmova Limited | 8 Billion INR | 98.569% |
| FDC Limited | 3.38 Billion INR | 96.615% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.87% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | 60.135% |
| Eris Lifesciences Limited | 6.98 Billion INR | 98.36% |
| Venus Remedies Limited | 711.8 Million INR | 83.902% |
| ZIM Laboratories Limited | 462.09 Million INR | 75.204% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 92.253% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | 49.783% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 98.147% |
| Shilpa Medicare Limited | 2.58 Billion INR | 95.572% |
| Albert David Limited | 1.04 Billion INR | 89.04% |
| Ajanta Pharma Limited | 12.56 Billion INR | 99.088% |
| Hester Biosciences Limited | 539.47 Million INR | 78.76% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 97.55% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 104.06% |
| Gufic Biosciences Limited | 1.48 Billion INR | 92.26% |
| Windlas Biotech Limited | 781.72 Million INR | 85.342% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 96.273% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -153.699% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | 34.504% |
| Granules India Limited | 8.6 Billion INR | 98.668% |
| Aarti Drugs Limited | 3.24 Billion INR | 96.473% |
| Bal Pharma Limited | 345.59 Million INR | 66.844% |
| Alkem Laboratories Limited | 24.19 Billion INR | 99.526% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.917% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 91.47% |
| Medicamen Biotech Limited | 245.66 Million INR | 53.357% |
| Unichem Laboratories Limited | 742.35 Million INR | 84.565% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -781.679% |
| Valiant Laboratories Limited | 12.73 Million INR | -799.466% |
| Orchid Pharma Limited | 1.41 Billion INR | 91.926% |
| Medico Remedies Limited | 129.09 Million INR | 11.241% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 98.33% |
| Ipca Laboratories Limited | 13.29 Billion INR | 99.138% |
| Brooks Laboratories Limited | 41.72 Million INR | -174.595% |
| Syncom Formulations (India) Limited | 430.27 Million INR | 73.37% |
| Piramal Enterprises Limited | -3.86 Billion INR | 102.968% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 99.673% |
| NATCO Pharma Limited | 18.79 Billion INR | 99.39% |
| Suven Life Sciences Limited | -992.78 Million INR | 111.542% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 238.507% |
| Strides Pharma Science Limited | 3.76 Billion INR | 96.956% |
| Indoco Remedies Limited | 2.64 Billion INR | 95.671% |
| Alpa Laboratories Limited | 229.96 Million INR | 50.173% |
| Lasa Supergenerics Limited | -65.08 Million INR | 276.065% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 103.071% |